Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 748
1.
Sci Rep ; 14(1): 12219, 2024 May 28.
Article En | MEDLINE | ID: mdl-38806680

Choroid plexus tumors (CPT) are rare and highly vascularized neoplasms that have three histologically confirmed diagnoses, including choroid plexus papilloma, atypical choroid plexus papilloma, and choroid plexus carcinoma (CPC). This study aimed to determine the epidemiology and survival of patients with CPTs and develop a nomogram to quantify the prognosis of the patients with CPT. Data of 808 patients who were diagnosed as CPT between 2000 and 2020 was obtained from the surveillance, epidemiology, and end results database. Descriptive analysis was used to assess the distribution and tumor-related characteristics of the patients with CPT. Independent prognostic factors for patients with CPT were identified by univariate and multivariate Cox regression analysis. The nomogram was established and evaluated by receiver operating characteristic curve, and decision curve analysis (DCA), calibration curves. The independent prognostic factors for patients with CPT are age, tumor size, surgery, chemotherapy, tumor number, pathologies, and race. For the prognostic nomogram, the area under the curve (AUC) of 60-, 120-, and 180-months were 0.855, 0.869 and 0.857 in the training set and 0.836, 0.864 and 0.922 in the test set. The DCA and calibration curve indicated the good performance of the nomogram. Patients with CPTs can be diagnosed at any age. Among the three histopathological tumors, patients with CPC had the worst prognosis. The nomogram was established to predict the prognosis of patients with CPT, which had satisfactory accuracy, and clinical utility may benefit for clinical decision-making.


Choroid Plexus Neoplasms , Nomograms , SEER Program , Humans , Choroid Plexus Neoplasms/pathology , Choroid Plexus Neoplasms/epidemiology , Choroid Plexus Neoplasms/diagnosis , Choroid Plexus Neoplasms/mortality , Female , Male , Prognosis , Middle Aged , Adult , Adolescent , Aged , Child , ROC Curve , Young Adult , Child, Preschool , Infant , Carcinoma
2.
Fluids Barriers CNS ; 21(1): 43, 2024 May 21.
Article En | MEDLINE | ID: mdl-38773599

The European Choroid plexus Scientific Forum (ECSF), held in Heidelberg, Germany between the 7th and 9th of November 2023, involved 21 speakers from eight countries. ECSF focused on discussing cutting-edge fundamental and medical research related to the development and functions of the choroid plexus and its implications for health, aging, and disease, including choroid plexus tumors. In addition to new findings in this expanding field, innovative approaches, animal models and 3D in vitro models were showcased to encourage further investigation into choroid plexus and cerebrospinal fluid roles.


Choroid Plexus , Humans , Animals , Cerebrospinal Fluid , Europe , Choroid Plexus Neoplasms
3.
Neuroradiology ; 66(5): 677-698, 2024 May.
Article En | MEDLINE | ID: mdl-38466393

PURPOSE: This article is the first in a two-part series designed to provide a comprehensive overview of the range of supratentorial intraventricular masses observed in children. Our primary objective is to discuss the diverse types of intraventricular masses that originate not only from cells within the choroid plexus but also from other sources. METHODS: In this article, we review relevant epidemiological data, the current genetics/molecular classification as outlined in the fifth edition of the World Health Organization's Classification of tumours of the Central Nervous System and noteworthy imaging findings. We conduct an exhaustive analysis of primary choroid plexus tumours as well as other conditions such as choroid plexus hyperplasia, choroid plexus cyst, choroid plexus xanthogranuloma, atypical teratoid rhabdoid tumour, meningioma, arteriovenous malformation and metastasis. RESULTS: We comprehensively evaluated each supratentorial intraventricular mass, providing an in-depth analysis of their unique clinical and histological characteristics. The fifth edition of the World Health Organization Classification of Tumours of the Central Nervous System introduces major modifications. These important changes could potentially have a profound impact on the management strategies and subsequent outcomes of these tumours. CONCLUSION: Intraventricular masses in children can arise from various sources. Surgical intervention is key for certain supratentorial intraventricular masses in paediatric patients, with preoperative neuroimaging essential to decide the best treatment approach, surgical or otherwise, as some cases may not require surgery.


Brain Neoplasms , Central Nervous System Neoplasms , Choroid Plexus Neoplasms , Meningeal Neoplasms , Humans , Child , Choroid Plexus Neoplasms/pathology , Neuroimaging
4.
Childs Nerv Syst ; 40(6): 1699-1705, 2024 Jun.
Article En | MEDLINE | ID: mdl-38316675

BACKGROUND: Choroid plexus carcinomas (CPCs) are rare, aggressive grade 3 tumors of the central nervous system associated with Li-Fraumeni syndrome (LFS) in a notable percentage of cases due to TP53 germline mutations. Understanding the correlation between CPCs and LFS is crucial for tailored management strategies. However, distinguishing CPCs from benign choroid plexus papillomas (CPPs) remains challenging, relying largely on histologic features. This study aimed to explore the association between CPCs and LFS, emphasizing the impact of TP53 mutations on diagnosis, treatment, and clinical outcomes. MATERIALS AND METHODS: Scientific databases such as PubMed, Scopus, and Web of Science were systematically searched up to January 2024 using keywords related to CPCs, LFS, TP53 mutation, and central nervous system tumors. Selection criteria included studies investigating the link between CPCs and LFS, their management approaches, and genetic implications of TP53 mutations. Ten relevant studies were selected for analysis after screening titles, abstracts, and full-text articles. Data extraction focused on clinical, genetic, and management factors related to CPCs associated with LFS. RESULTS: The review highlighted the strong association (36%) between CPCs and LFS, primarily due to TP53 germline mutations. Studies emphasized the need for genetic testing in patients with CPCs, especially in pediatric cases, to identify LFS implications. Furthermore, the impact of TP53 mutations on treatment strategies was emphasized, recommending irradiation-sparing therapies due to inferior survival rates associated with radiotherapy in LFS patients with CPCs. Cases illustrated the challenges in diagnosing CPCs and the importance of immunohistochemistry and genetic testing for TP53 mutations. CONCLUSION: CPCs pose challenges in diagnosis and management, particularly in distinguishing them from benign tumors. The association with LFS, often due to TP53 germline mutations, underscores the importance of genetic testing for early detection and tailored treatment strategies. Irradiation-sparing therapies are recommended for LFS-associated CPCs to mitigate the risk of secondary malignancies. Comprehensive profiling of CPC patients, especially in pediatric cases, is crucial for early detection and management of potential secondary cancers associated with LFS.


Carcinoma , Choroid Plexus Neoplasms , Li-Fraumeni Syndrome , Tumor Suppressor Protein p53 , Female , Humans , Male , Carcinoma/genetics , Carcinoma/therapy , Choroid Plexus Neoplasms/genetics , Choroid Plexus Neoplasms/therapy , Germ-Line Mutation , Li-Fraumeni Syndrome/genetics , Li-Fraumeni Syndrome/therapy , Li-Fraumeni Syndrome/complications , Mutation , Tumor Suppressor Protein p53/genetics , Child
5.
J Neurooncol ; 166(1): 27-38, 2024 Jan.
Article En | MEDLINE | ID: mdl-38190092

PURPOSE: Choroid plexus carcinomas (CPCs) are extremely rare brain tumors and carry a dismal prognosis. Treatment options are limited and there is an urgent need to develop models to further research. In the present study, we established two CPC cell lines and performed multi-omics analyses. These cell lines serve as valuable models to propose new treatments in these rare but deadly brain tumors. METHODS: Multi-omic profiling including, (i) methylation array (EPIC 850 K), (ii) whole genome sequencing (WGS), (iii) CANCERPLEX cancer genome panel testing, (iv) RNA sequencing (RNA-seq), and (v) proteomics analyses were performed in CCHE-45 and NGT131 cell lines. RESULTS: Both cell lines were classified as methylation class B. Both harbored pathogenic TP53 point mutations; CCHE-45 additionally displayed TP53 loss. Furthermore, alterations of the NOTCH and WNT pathways were also detected in both cell lines. Two protein-coding gene fusions, BZW2-URGCP, and CTTNBP2-ERBB4, mutations of two oncodrivers, GBP-4 and KRTAP-12-2, and several copy number alterations were observed in CCHE-45, but not NGT131. Transcriptome and proteome analysis identified shared and unique signatures, suggesting that variability in choroid plexus carcinoma tumors may exist. The discovered difference's importance and implications highlight the possible diversity of choroid plexus carcinoma and call for additional research to fully understand disease pathogenesis. CONCLUSION: Multi-omics analyses revealed that the two choroid plexus carcinoma cell lines shared TP53 mutations and other common pathway alterations and activation of NOTCH and WNT pathways. Noticeable differences were also observed. These cell lines can serve as valuable models to propose new treatments in these rare but deadly brain tumors.


Carcinoma , Choroid Plexus Neoplasms , Multiomics , Humans , Tumor Suppressor Protein p53/genetics , Choroid Plexus Neoplasms/genetics , Choroid Plexus Neoplasms/pathology , Cell Line , Choroid Plexus/chemistry , Choroid Plexus/metabolism , Choroid Plexus/pathology , DNA-Binding Proteins/metabolism
7.
World Neurosurg ; 181: e1071-e1087, 2024 Jan.
Article En | MEDLINE | ID: mdl-37977483

OBJECTIVE: Optimal choroid plexus tumor (CPT) treatment involves gross total resection; however, intraoperative hemorrhage risk remains significant given tumor vascularity. This study describes pediatric CPT management and identifies patients most likely to benefit from preoperative embolization. METHODS: CPTs resected from 1997 to 2021 were included. The characteristics of embolized patients were compared to nonembolized patients; nonembolized patients were further stratified based on open vascular control-pedicle feeder ligation versus no pedicle ligation prior to tumor debulking. Statistical analyses identified factors associated with estimated blood loss (EBL), transfusion, length of stay, and complications. RESULTS: Among the 46 CPT cases identified, 98% achieved gross total resection, and 15% received embolization. Embolized patients were younger, smaller, and had larger tumors compared to nonembolized patients (median: 0.8 vs. 2.1 years; 9.3 vs. 14.4 kg; 91.08 vs. 5.5 cm3). Transfused patients were similarly younger and smaller (P < 0.05) than nontransfused patients. Among nonembolized patients, open vascular control was achieved in smaller tumors (<13 cm3) with significantly lower EBL (P = 0.002). Higher EBL was observed in patients with larger tumors, hydrocephalus, transependymal edema, vomiting, lethargy, and developmental regression (all P < 0.05). Patients with lethargy had longer hospital stays and a higher likelihood of postoperative complications (P < 0.05). There were no significant differences in complication rates between the embolization and nonembolization groups. CONCLUSIONS: Despite higher surgical risk profiles, embolized patients had similar complication rates and postoperative hydrocephalus management as nonembolized patients. Embolization was particularly beneficial in patients at high risk for surgical morbidity, such as those <2 years, weighing <10 kg, and with a tumor volume >15 cm3.


Choroid Plexus Neoplasms , Embolization, Therapeutic , Hydrocephalus , Papilloma, Choroid Plexus , Child , Humans , Lethargy/complications , Choroid Plexus Neoplasms/surgery , Choroid Plexus Neoplasms/complications , Hydrocephalus/surgery , Hydrocephalus/complications , Blood Loss, Surgical , Embolization, Therapeutic/adverse effects , Retrospective Studies , Papilloma, Choroid Plexus/complications
8.
Childs Nerv Syst ; 40(2): 453-462, 2024 Feb.
Article En | MEDLINE | ID: mdl-37726497

PURPOSE: Choroid plexus tumors (CPT) are relatively rare CNS tumors that primarily occur in children. They are classified as low-grade choroid plexus papilloma, including atypical ones, and high-grade choroid plexus carcinoma based on histological characteristics. There has been extensive academic research regarding these complex tumors. The goal of this work was to identify the 100 most-cited articles pertaining to CPTs in order to better understand the most impactful studies to date. METHODS: In August 2023, Elsevier's Scopus database was searched for the 100 most-cited articles about CPT. To look for trends, articles were classified as either basic science or clinical, and the earliest 50 articles were separated from the latest 50 articles and then were compared. Various bibliometric parameters were summarized and compared using Pearson's chi-square exact test and Wilcoxon rank sum test/Mann-Whitney U test. RESULTS: The 100 most-cited articles were published between 1955 and 2016 in 53 different scientific journals, originating from 16 distinct countries. Over 75% of the articles were clinical in nature, and overall mean (range) values were as follows: citation count 78.5 (42-371), citation rate per year 3.4 (0.9-12), number of authors 6.2 (1-28). Newer articles had statistically higher citation rate (P < 0.01) and number of authors (P < 0.01) compared to their older counterparts. Additionally, while there was no significant difference in article focus (P = 0.64), there was a difference in study design (P < 0.01). CONCLUSION: This study used citation number as a surrogate for article impact and identified the 100 most-cited CPT articles. New mutational analyses have allowed for further subgrouping and positive trends in collaboration shine hope for improvement in treatment outcomes and long-term survival.


Choroid Plexus Neoplasms , Papilloma, Choroid Plexus , Child , Humans , Bibliometrics , Choroid Plexus Neoplasms/pathology , Papilloma, Choroid Plexus/pathology , Treatment Outcome , Research Design
9.
Adv Biol (Weinh) ; 8(2): e2300185, 2024 Feb.
Article En | MEDLINE | ID: mdl-37884455

This study compares the impact of two isolation methods, ultracentrifugation (UC) and size exclusion chromatography (SEC), on small extracellular vesicles (sEVs) from primary human cardiac mesenchymal-derived progenitor cells (CPCs). sEV_UC and sEV_SEC exhibit similar size, marker expression, and miRNA cargo, but sEV_UC contains notably higher total protein levels. In vitro assays show that sEV_UC, despite an equal particle count, induces more robust ERK phosphorylation, cytoprotection, and proliferation in iPS-derived cardiomyocytes (iPS-CMs) compared to sEV_SEC. sEV_UC also contains elevated periostin (POSTN) protein levels, resulting in enhanced focal adhesion kinase (FAK) phosphorylation in iPS-CMs. Importantly, this effect persists with treatment with soluble free-sEV protein fraction from SEC (Prote_SEC), indicating that free proteins like POSTN in sEV_UC enhance FAK phosphorylation. In vivo, sEV contamination with soluble proteins doesn't affect cardiac targeting or FAK phosphorylation, underscoring the intrinsic tissue targeting properties of sEV. These findings emphasize the need for standardized sEV isolation methods, as the choice of method can impact experimental outcomes, particularly in vitro.


Carcinoma , Choroid Plexus Neoplasms , Extracellular Vesicles , Humans , Focal Adhesion Protein-Tyrosine Kinases , Chromatography, Gel
10.
J Pak Med Assoc ; 73(12): 2483-2487, 2023 Dec.
Article En | MEDLINE | ID: mdl-38083939

The objective of this study is to report clinical, radiological, and histopathological characteristics of three paediatric patients diagnosed as Choroid plexus carcinoma seen at our hospital, between 2015 and 2020. Three patients were diagnosed with choroid plexus carcinomas between 2015 and 2018. The mean age at diagnosis was 1.3 years (range 8 months to 1.5 years). All the three patients had subtotal resection and received adjuvant chemotherapy. One patient also received adjuvant radiotherapy. Despite these treatment measures, residual disease was noted in all three patients and two patients were subsequently treated on palliative care grounds. The average duration of follow-up after the first surgery for all three patients was approximately 33 months. Attaining satisfactory outcome in patients with CPC is challenging. Our case series reflects the difficulty in achieving gross total resection and ensuring that the disease does not recur.


Choroid Plexus Neoplasms , Papilloma, Choroid Plexus , Child , Humans , Infant , Papilloma, Choroid Plexus/diagnosis , Papilloma, Choroid Plexus/pathology , Papilloma, Choroid Plexus/surgery , Retrospective Studies , Neoplasm Recurrence, Local , Choroid Plexus Neoplasms/diagnosis , Choroid Plexus Neoplasms/therapy , Choroid Plexus Neoplasms/pathology
12.
World Neurosurg ; 179: 43-44, 2023 Nov.
Article En | MEDLINE | ID: mdl-37562679

Choroid plexus papillomas are highly vascular tumors, and such tumors causing subarachnoid hemorrhage have been reported in literature. Similarly, few articles have reported atypical fourth ventricular choroid plexus tumors in adults. However, such an atypical tumor presenting with grossly hemorrhagic transformation without any acute symptoms could not be found in the literature.


Choroid Plexus Neoplasms , Glioma , Papilloma, Choroid Plexus , Adult , Humans , Papilloma, Choroid Plexus/complications , Papilloma, Choroid Plexus/diagnostic imaging , Papilloma, Choroid Plexus/surgery , Fourth Ventricle/diagnostic imaging , Fourth Ventricle/surgery , Fourth Ventricle/pathology , Magnetic Resonance Imaging , Choroid Plexus Neoplasms/diagnostic imaging , Choroid Plexus Neoplasms/surgery , Glioma/pathology , Choroid Plexus/pathology
13.
Adv Exp Med Biol ; 1405: 175-223, 2023.
Article En | MEDLINE | ID: mdl-37452939

Tumors arising inside the ventricular system are rare but represent a difficult diagnostic and therapeutic challenge. They usually are diagnosed when reaching a big volume and tend to affect young children. There is a wide broad of differential diagnoses with significant variability in anatomical aspects and tumor type. Differential diagnosis in tumor type includes choroid plexus tumors (papillomas and carcinomas), ependymomas, subependymomas, subependymal giant cell astrocytomas (SEGAs), central neurocytomas, meningiomas, and metastases. Choroid plexus tumors, ependymomas of the posterior fossa, and SEGAs are more likely to appear in childhood, whereas subependymomas, central neurocytomas, intraventricular meningiomas, and metastases are more frequent in adults. This chapter is predominantly focused on choroid plexus tumors and radiological and histological differential diagnosis. Treatment is discussed in the light of the modern acquisition in genetics and epigenetics of brain tumors.


Choroid Plexus Neoplasms , Ependymoma , Glioma, Subependymal , Neurocytoma , Child , Adult , Humans , Child, Preschool , Choroid Plexus , Choroid Plexus Neoplasms/diagnosis , Choroid Plexus Neoplasms/genetics , Choroid Plexus Neoplasms/therapy , Ependymoma/diagnosis , Ependymoma/genetics , Ependymoma/therapy
14.
Childs Nerv Syst ; 39(12): 3415-3420, 2023 Dec.
Article En | MEDLINE | ID: mdl-37166543

BACKGROUND: Tumors of the choroid plexus of the third ventricle are uncommon. Surgical excision is technically challenging because of the rich vascularisation, central location, and high incidence in young children. Open microsurgical resection is considered the standard treatment. However, attempts at purely endoscopic removal of choroid plexus tumors of the third ventricle have also been made in the past, with encouraging results. CASE REPORTS: We report our experience with endoscopic ultrasonic removal of two cases of tumors of the third ventricular choroid plexus. The first case was a large atypical choroid plexus papilloma (WHO grade 2) in the anterior third ventricle associated with hydrocephalus; the second case was a smaller choroid plexus papilloma (WHO grade 1) in the middle/posterior third ventricle without overt hydrocephalus requiring a more anterior neuronavigation guided approach. DISCUSSION AND CONCLUSION: Choroid plexus papillomas of the third ventricle can be safely treated by a purely endoscopic approach because they are usually smaller than their counterparts in the lateral ventricle and often have a recognizable vascular pedicle. Early detection and control of the vascular pedicle at the choroidal border is key to success. The use of ultrasonic aspirator facilitates and expedites endoscopic access. By alternating surface coagulation with fragmentation and aspiration with the ultrasonic aspirator, the tumor can be removed without difficult dissection maneuvers.


Choroid Plexus Neoplasms , Hydrocephalus , Papilloma, Choroid Plexus , Third Ventricle , Child, Preschool , Humans , Choroid Plexus/surgery , Choroid Plexus Neoplasms/diagnostic imaging , Choroid Plexus Neoplasms/surgery , Endoscopy , Hydrocephalus/diagnostic imaging , Hydrocephalus/etiology , Hydrocephalus/surgery , Papilloma, Choroid Plexus/diagnostic imaging , Papilloma, Choroid Plexus/surgery , Third Ventricle/diagnostic imaging , Third Ventricle/surgery , Third Ventricle/pathology , Ultrasonics
15.
J Vet Intern Med ; 37(4): 1493-1500, 2023.
Article En | MEDLINE | ID: mdl-37224288

Obstructive or nonobstructive hypertensive hydrocephalus is reported in choroid plexus tumors. Choroid plexus tumors typically present as T2-weighted hyperintense intraventricular masses with occasional cerebrospinal fluid-drop metastasis. Acquired neoplastic nonobstructive hydrocephalus without visible mass lesion in magnetic resonance imaging is not reported in dogs. A 4.5-year-old Rhodesian Ridgeback presented with reduced mental status, unilaterally absent pupillary light reflex, and neck pain. Magnetic resonance imaging revealed a nonobstructive hydrocephalus and widened lumbar subarachnoid space with no evidence of a primary mass lesion. Postmortem examination confirmed a disseminated choroid plexus tumor affecting the ependyma and choroid plexi of all ventricles and the cerebral and lumbar subarachnoid space. Disseminated choroid plexus carcinomatosis should be considered as a possible cause of hypertensive hydrocephalus even in absence of a primary mass.


Carcinoma , Choroid Plexus Neoplasms , Dog Diseases , Hydrocephalus , Dogs , Animals , Choroid Plexus/diagnostic imaging , Choroid Plexus/pathology , Hydrocephalus/diagnostic imaging , Hydrocephalus/veterinary , Choroid Plexus Neoplasms/complications , Choroid Plexus Neoplasms/diagnostic imaging , Choroid Plexus Neoplasms/veterinary , Magnetic Resonance Imaging/veterinary , Carcinoma/complications , Carcinoma/diagnostic imaging , Carcinoma/veterinary , Dog Diseases/diagnosis
16.
Arch. Soc. Esp. Oftalmol ; 98(5): 281-291, mayo 2023. ilus, tab
Article Es | IBECS | ID: ibc-219937

El hemangioma coroideo es un tumor vascular benigno dependiente de la circulación coroidea. Se distinguen 2tipos de lesiones: circunscrita, variante más frecuente, y difusa, asociada normalmente al síndrome de Sturge-Weber. El hemangioma coroideo circunscrito se presenta como una masa anaranjada que puede aparecer de manera asintomática, sin embargo, cuando produce síntomas, lo más frecuente es la disminución de la agudeza visual debido a un desprendimiento de retina neurosensorial. Debido a su carácter benigno solo deberían ser subsidiarios de tratamiento aquellos que produzcan síntomas. El conocimiento de esta enfermedad y su correcto diagnóstico diferencial es muy relevante para establecer el diagnóstico y tratamiento adecuado y evitar tratamientos innecesarios. En la actualidad existe una gran variedad de pruebas de imagen de diagnóstico multimodal que nos permiten identificar y realizar un seguimiento adecuado de este tumor. Además, en los últimos años, gracias al empleo de la terapia fotodinámica, se ha producido un cambio en el paradigma del tratamiento de estas lesiones, lo cual ha supuesto una mejora significativa en el pronóstico visual de estos pacientes. Esto se ha debido al empleo de la terapia fotodinámica, como tratamiento de elección para el hemangioma coroideo circunscrito (AU)


Choroidal hemangiomais a benign vascular tumor dependent on the choroid. Two types of lesions are distinguished: circumscribed, the most frequent variant, and diffuse, normally associated with Sturge-Weber syndrome. The circumscribed choroidal hemangioma appears as an orange mass that can present asymptomatically, however, when it produces symptoms, the most frequent is decreased visual acuity due to neurosensory retinal detachment. Due to its benign nature, only those that produce symptoms should be eligible for treatment. Knowledge of this pathology and its correct differential diagnosis is very relevant to establish the appropriate diagnosis and treatment, avoiding unnecessary treatments. There is currently a wide variety of multimodal diagnostic imaging tests that allow us to identify and adequately monitor this tumor. In addition, in recent years, there has been a change in the paradigm of the treatment of these tumors thanks to the use of photodinamic therapy, which has led to a significant improvement in the visual prognosis of these patients. This has been due to the use of photodynamic therapy as the treatment of choice for circumscribed choroidal hemangioma (AU)


Humans , Hemangioma/diagnostic imaging , Hemangioma/therapy , Choroid Plexus Neoplasms/diagnostic imaging , Choroid Plexus Neoplasms/therapy , Diagnosis, Differential
17.
J Control Release ; 357: 580-590, 2023 05.
Article En | MEDLINE | ID: mdl-37054779

Choroid plexus carcinoma (CPC) is a rare infantile brain tumor with an aggressive clinical course that often leaves children with debilitating side effects due to aggressive and toxic chemotherapies. Development of novel therapeutical strategies for this disease have been extremely limited owing to the rarity of the disease and the paucity of biologically relevant substrates. We conducted the first high-throughput screen (HTS) on a human patient-derived CPC cell line (Children Cancer Hospital Egypt, CCHE-45) and identified 427 top hits highlighting key molecular targets in CPC. Furthermore, a combination screen with a wide variety of targets revealed multiple synergistic combinations that may pave the way for novel therapeutical strategies against CPC. Based on in vitro efficiency, central nervous system (CNS) penetrance ability and feasible translational potential, two combinations using a DNA alkylating or topoisomerase inhibitors in combination with an ataxia telangiectasia mutated and rad3 (ATR) inhibitor (topotecan/elimusertib and melphalan/elimusertib respectively) were validated in vitro and in vivo. Pharmacokinetic assays established increased brain penetrance with intra-arterial (IA) delivery over intra-venous (IV) delivery and demonstrated a higher CNS penetrance for the combination melphalan/elimusertib. The mechanisms of synergistic activity for melphalan/elimusertib were assessed through transcriptome analyses and showed dysregulation of key oncogenic pathways (e.g. MYC, mammalian target of rapamycin mTOR, p53) and activation of critical biological processes (e.g. DNA repair, apoptosis, hypoxia, interferon gamma). Importantly, IA administration of melphalan combined with elimusertib led to a significant increase in survival in a CPC genetic mouse model. In conclusion, this study is, to the best of our knowledge, the first that identifies multiple promising combinatorial therapeutics for CPC and emphasizes the potential of IA delivery for the treatment of CPC.


Carcinoma , Choroid Plexus Neoplasms , Child , Humans , Mice , Animals , Melphalan , Choroid Plexus Neoplasms/drug therapy , Choroid Plexus Neoplasms/genetics , Choroid Plexus Neoplasms/pathology , Topotecan , Mammals
20.
Article En | MEDLINE | ID: mdl-36963804

Choroid plexus tumors (CPTs) are rare intracranial neoplasms, representing <1% of all brain tumors, yet they represent 20% of first-year pediatric brain tumors. Although these tumors have been linked to TP53 germline mutations in the context of Li-Fraumeni syndrome, their somatic driver alterations remain poorly understood. In this study, we report two cases of lateral ventricle tumors: 3-yr-old male diagnosed with an atypical choroid plexus papilloma (aCPP), and a 6-mo-old female diagnosed with a choroid plexus carcinoma (CPC). We performed whole-exome sequencing of paired blood and tumor tissue in both patients, categorized somatic variants, and determined copy-number alterations. Our analysis revealed a tier II variant (Association for Molecular Pathology [AMP] criteria) in BRD1, a H3 and TP53 acetylation agent, in the aCPP. In addition, we detected copy-number gains on Chromosomes 12, 18, and 20 and copy-number losses on Chromosomes 13q and 22q (BRD1 locus) in this tumor. The CPC tumor had only a pathogenic germline TP53 variant, based on American College of Medical Genetics (ACMG) criteria, with a clinical and familiar history of Li-Fraumeni syndrome. The CPC patient presented loss of heterozygosity (LoH) of TP53 loci and hyperdiploid genome. Both tumors were microsatellite-stable. This is the first study performing whole-exome sequencing in Brazilian choroid plexus tumors, and in line with the literature, we corroborate the absence of recurrent somatic mutations in these tumors. Further studies with larger sample sizes are necessary to confirm our findings and better understand the underlying biology of these tumors.


Choroid Plexus Neoplasms , Li-Fraumeni Syndrome , Child , Humans , Male , Female , United States , Li-Fraumeni Syndrome/genetics , Brazil , Exome Sequencing , Choroid Plexus Neoplasms/genetics , Choroid Plexus Neoplasms/pathology , Genomics
...